EP08.02-118 TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors

N. Misako, S. Sugawara, C.-M. Choi, T. Okamoto, N. Yanagitani, K. Nosaki, T. Takahashi, Y. Fujiwara, H. Hayashi, J. Khoury, J. Nieva,A.E. Gabayan, L.E. Raez, H. Chen, A. Dimou, N. Pennell, G. Liu, S.-H.I. Ou, T. Seto, Y. Ohe

Journal of Thoracic Oncology（2022）

引用 0|浏览0

暂无评分

摘要

Taletrectinib (AB-106/DS-6051b) is a next-generation, brain-penetrant, ROS1/ NTRK tyrosine kinase inhibitor (TKI) and has shown clinically meaningful effect and safety profile in ROS1+ Non-Small Cell Lung Cancer (NSCLC) patients in phase 1 studies (Fujiwara et al, Oncotarget 2018; 9(34): 23729-23737; Ou et al, JTO Clin Res Rep. 2020 Oct 21;2(1):100108). Taletrectinib has also demonstrated activity against ROS1 G2032R resistance mutation and CNS metastases in the ongoing phase 2 TRUST study (NCT04395677) in China. Also, taletrectinib has shown preliminary efficacy against NTRK positive solid tumors in an ongoing phase 2 study (NCT04617054)

查看译文

关键词

lung cancer,other solid tumors,solid tumors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要